Aligos Therapeutics, Inc. (ALGS) stock
ALGSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 7/3010% below fair value
$2.10+0.12 (+6.06%)
Close on Nov 13, 2026Market cap $26.23MP/E –Yield –
Aligos Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Aligos Therapeutics's operating cash flow for the twelve months ending Sep 30, 2026 was -$68.37M. For fiscal 2025 it was -$82.50M. The highest annual figure on record is -$46.77M in fiscal 2019.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$82.50M | – |
| FY2024 | Dec 31, 2024 | -$80.74M | – |
| FY2023 | Dec 31, 2023 | -$79.00M | – |
| FY2022 | Dec 31, 2022 | -$79.39M | – |
| FY2021 | Dec 31, 2021 | -$115.66M | – |
| FY2020 | Dec 31, 2020 | -$74.26M | – |
| FY2019 | Dec 31, 2019 | -$46.77M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $1.45M | – |
| Q2 FY2026 | Jun 30, 2026 | -$24.95M | – |
| Q1 FY2026 | Mar 31, 2026 | -$23.13M | – |
| Q4 FY2025 | Dec 31, 2025 | -$21.75M | – |
| Q3 FY2025 | Sep 30, 2025 | -$24.35M | – |
| Q2 FY2025 | Jun 30, 2025 | -$15.50M | – |
| Q1 FY2025 | Mar 31, 2025 | -$20.91M | – |
| Q4 FY2024 | Dec 31, 2024 | -$18.40M | – |
| Q3 FY2024 | Sep 30, 2024 | -$20.10M | – |
| Q2 FY2024 | Jun 30, 2024 | -$19.49M | – |
| Q1 FY2024 | Mar 31, 2024 | -$22.75M | – |
| Q4 FY2023 | Dec 31, 2023 | -$22.66M | – |
| Q3 FY2023 | Sep 30, 2023 | -$20.34M | – |
| Q2 FY2023 | Jun 30, 2023 | -$13.62M | – |
| Q1 FY2023 | Mar 31, 2023 | -$22.39M | – |
| Q4 FY2022 | Dec 31, 2022 | -$16.78M | – |
| Q3 FY2022 | Sep 30, 2022 | -$17.14M | – |
| Q2 FY2022 | Jun 30, 2022 | -$25.04M | – |
| Q1 FY2022 | Mar 31, 2022 | -$20.43M | – |
| Q4 FY2021 | Dec 31, 2021 | -$37.48M | – |
| Q3 FY2021 | Sep 30, 2021 | -$25.37M | – |
| Q2 FY2021 | Jun 30, 2021 | -$23.02M | – |
| Q1 FY2021 | Mar 31, 2021 | -$29.80M | – |
| Q4 FY2020 | Dec 31, 2020 | -$19.68M | – |
| Q3 FY2020 | Sep 30, 2020 | -$16.57M | – |
| Q2 FY2020 | Jun 30, 2020 | -$17.69M | – |
| Q1 FY2020 | Mar 31, 2020 | -$20.32M | – |
| Q4 FY2019 | Dec 31, 2019 | -$15.02M | – |
See a number that looks wrong?